The newest generation of metabolic peptides can sound confusing because many of them target several hormone pathways at the same time. GLP-1. GIP. Glucagon. Amylin. These names now appear repeatedly in discussions around compounds such as: semaglutide tirzepatide retatrutide cagrilintide petrelintide eloralintide CagriSema zenagamtide survodutide mazdutide But these pathways are not interchangeable. Each hormone performs...Read More
Metabolic peptide research has moved remarkably quickly. First came single-receptor GLP-1 agonists. Then dual agonists targeting combinations such as: GLP-1 + GIP GLP-1 + glucagon Then came triple agonists such as retatrutide, designed to activate: GLP-1 GIP glucagon Now researchers are beginning to explore something even broader: five-receptor polypharmacology. A 2026 Nature Metabolism study combining...Read More
Retatrutide is already unusual. It is a single investigational peptide designed to activate three metabolic hormone receptors at once: GIP GLP-1 glucagon That makes it a triple agonist. But a newer idea is now beginning to emerge around retatrutide: What happens if a triple agonist becomes the foundation for an even broader combination therapy? Online,...Read More
CagriSema is one of the most important examples of where metabolic peptide research is heading next. Instead of relying on GLP-1 alone, CagriSema combines two separate peptide pathways: cagrilintide, a long-acting amylin analogue semaglutide, a GLP-1 receptor agonist The idea is simple but biologically powerful: GLP-1 and amylin regulate appetite through overlapping but distinct mechanisms....Read More
For several years, GLP-1 dominated metabolic peptide research. Now another naturally occurring hormone is moving rapidly into the spotlight: amylin. Amylin-based drugs are being studied on their own, alongside GLP-1 therapies, alongside GIP/GLP-1 dual agonists, and even experimentally with triple agonists such as retatrutide. That has made amylin one of the most important emerging pathways...Read More
Retatrutide has already attracted huge interest because one molecule targets three metabolic hormone receptors simultaneously. Cagrilintide approaches appetite regulation through a completely different pathway: amylin. Now researchers have combined the two. A peer-reviewed study published in Nature Metabolism in 2026 investigated cagrilintide and retatrutide together in an experimental obesity model. The results have generated considerable...Read More
Dapiglutide is one of the more unusual experimental metabolic peptides because it was designed to do more than influence appetite and body weight. It combines activity at two receptors: GLP-1 GLP-2 GLP-1 is already well known for its role in appetite and glucose regulation. GLP-2 is very different. It is involved primarily in intestinal growth,...Read More
Most modern obesity medicines are built around one familiar idea: activate GLP-1 signalling, sometimes together with another metabolic receptor. MariTide, also known as maridebart cafraglutide and previously AMG 133, takes a much less conventional approach. It is an antibody–peptide conjugate that: activates the GLP-1 receptor blocks the GIP receptor rather than stimulating both receptors simultaneously....Read More
Mazdutide is one of the clearest examples of how rapidly next-generation peptide therapies are moving from experimental research into real clinical use. Also known by its development code IBI362, mazdutide is a once-weekly dual GLP-1 and glucagon receptor agonist peptide developed by Innovent Biologics in collaboration with Eli Lilly. Unlike therapies that primarily target GLP-1...Read More
The next generation of metabolic peptides is increasingly moving beyond single- and dual-receptor agonists. Efocipegtrutide, previously known as HM15211, is one of the more unusual examples. It is a long-acting experimental peptide designed to activate three metabolic hormone receptors simultaneously: GLP-1 GIP glucagon But unlike several triple agonists being developed primarily for obesity, efocipegtrutide has...Read More
